| Systematic (IUPAC) name | |
|---|---|
| (6aS)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Uncontrolled |
| Routes | Oral |
| Identifiers | |
| CAS number | 57559-68-9 |
| ATC code | None |
| PubChem | CID 5311191 |
| ChemSpider | 4470712 |
| Chemical data | |
| Formula | C19H21NO2 |
| Mol. mass | 295.38 g/mol |
| SMILES | eMolecules & PubChem |
N-n-Propylnorapomorphine (NPA) is an aporphine derivative dopamine agonist closely related to apomorphine.[1][2] In rodents it has been shown to produce hyperactivity, stereotypy, hypothermia, antinociception, and penile erection, among other effects.[3][4][5][6] Notably, its effects on locomotion are biphasic, with low doses producing inhibition and catalepsy and high doses resulting in enhancement of activity.[7] This is likely due to preferential activation of D2/D3 autoreceptors versus postsynaptic receptors,[8] the latter of which overpowers the former only with high doses.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)